Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease

Michal Benderly; Batya Sapir; Ofra Kalter-Leibovici; Reuven Zimlichman

doi:10.3109/1354750X.2016.1171910

Lipoprotein-associated phospholipase A₂, and subsequent cardiovascular events and mortality among patients with coronary heart disease

Michal Benderly^*, Batya Sapir, Ofra Kalter-Leibovici, Reuven Zimlichman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objective: The objective of this study is to evaluate the relevance of Lp-PLA₂ to risk prediction among coronary heart disease (CHD) patients. Methods: Lp-PLA₂ activity was measured in 2538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Results: Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA₂ was associated with a hazard ratio (HR) of 1.12 (95% confidence interval (CI): 1.00–1.25) for mortality and 1.03 (0.93–1.14) for cardiovascular events. Lp-PLA₂ did not significantly improve model discrimination, or calibration nor result in noteworthy reclassification. Conclusions: Our results do not support added value of Lp-PLA₂ for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.

Original language	English
Pages (from-to)	219-224
Number of pages	6
Journal	Biomarkers
Volume	22
Issue number	3-4
DOIs	https://doi.org/10.3109/1354750X.2016.1171910
State	Published - 19 May 2017

Keywords

Cohort study
risk factors
risk prediction

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/1354750X.2016.1171910

Cite this

@article{529a216f60f24196b3086221d8c656a2,

title = "Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease",

abstract = "Objective: The objective of this study is to evaluate the relevance of Lp-PLA2 to risk prediction among coronary heart disease (CHD) patients. Methods: Lp-PLA2 activity was measured in 2538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Results: Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA2 was associated with a hazard ratio (HR) of 1.12 (95% confidence interval (CI): 1.00–1.25) for mortality and 1.03 (0.93–1.14) for cardiovascular events. Lp-PLA2 did not significantly improve model discrimination, or calibration nor result in noteworthy reclassification. Conclusions: Our results do not support added value of Lp-PLA2 for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.",

keywords = "Cohort study, risk factors, risk prediction",

author = "Michal Benderly and Batya Sapir and Ofra Kalter-Leibovici and Reuven Zimlichman",

note = "Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = may,

day = "19",

doi = "10.3109/1354750X.2016.1171910",

language = "אנגלית",

volume = "22",

pages = "219--224",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "3-4",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease

AU - Benderly, Michal

AU - Sapir, Batya

AU - Kalter-Leibovici, Ofra

AU - Zimlichman, Reuven

PY - 2017/5/19

Y1 - 2017/5/19

N2 - Objective: The objective of this study is to evaluate the relevance of Lp-PLA2 to risk prediction among coronary heart disease (CHD) patients. Methods: Lp-PLA2 activity was measured in 2538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Results: Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA2 was associated with a hazard ratio (HR) of 1.12 (95% confidence interval (CI): 1.00–1.25) for mortality and 1.03 (0.93–1.14) for cardiovascular events. Lp-PLA2 did not significantly improve model discrimination, or calibration nor result in noteworthy reclassification. Conclusions: Our results do not support added value of Lp-PLA2 for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.

AB - Objective: The objective of this study is to evaluate the relevance of Lp-PLA2 to risk prediction among coronary heart disease (CHD) patients. Methods: Lp-PLA2 activity was measured in 2538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Results: Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA2 was associated with a hazard ratio (HR) of 1.12 (95% confidence interval (CI): 1.00–1.25) for mortality and 1.03 (0.93–1.14) for cardiovascular events. Lp-PLA2 did not significantly improve model discrimination, or calibration nor result in noteworthy reclassification. Conclusions: Our results do not support added value of Lp-PLA2 for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.

KW - Cohort study

KW - risk factors

KW - risk prediction

UR - http://www.scopus.com/inward/record.url?scp=84964430230&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2016.1171910

DO - 10.3109/1354750X.2016.1171910

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 27097870

AN - SCOPUS:84964430230

SN - 1354-750X

VL - 22

SP - 219

EP - 224

JO - Biomarkers

JF - Biomarkers

IS - 3-4

ER -